妇科肿瘤免疫治疗的新靶点  

Emerging Targets of Immunotherapy in Gynecologic Cancer

作　　者：程红燕 向阳[1] Cheng Hongyan;Xiang Yang(Department of Obstetrics and Gynecology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院/北京协和医学院/北京协和医院妇产科,北京100730

出　　处：《肿瘤预防与治疗》2021年第5期392-400,共9页Journal of Cancer Control And Treatment

基　　金：国家自然科学基金(编号:81971475、81972451);中国医学科学院医学与健康科技创新工程(编号:CAMS-2017-I2M-1-002)。

摘　　要：虽然作用于程序性细胞死亡蛋白1/程序性死亡配体1(PD-1/PD-L1)和细胞毒性T淋巴细胞抗原4(CT-LA-4)的抗体已成功应用于晚期实体瘤的治疗,但其疗效仍不够高.需寻找新的免疫靶点以便为难治性肿瘤患者寻求替代治疗.根据受体与配体结合后发挥的作用,可将免疫靶点分为共刺激分子和共抑制分子,共抑制分子包括:T细胞免疫球蛋白黏蛋白-3(TIM-3)、含免疫球蛋白及ITIM结构域的T细胞免疫受体(TIGIT)、淋巴细胞活化基因3(LAG-3)、T细胞激活抑制物免疫球蛋白可变区结构域(VISTA)以及B7家族的B7-H3和B7-H4;共刺激分子包括CD27、OX40、4-1BB、CD40,糖皮质激素诱导的肿瘤坏死因子受体(GITR)和诱导共刺激因子(ICOS)等.本文就新兴的免疫靶点在妇科恶性肿瘤的临床前和临床研究进展作一简要阐述.Although programmed cell death protein 1/programmed death-ligand 1(PD-1/PD-L1) and cytotoxic T lymphocyte antigen-4(CTLA-4) have been successfully applied in the treatment of tumors, their efficiency is still not high enough. New immune targets need to be identified in order to seek alternative treatment strategies for patients with refractory tumors. Immune targets can be divided into stimulating and inhibiting molecules according to their functions after receptor-ligand binding. These targets include co-inhibitory molecules, such as T cell immunoglobulin-3(TIM-3), T cell immunoglobulin and ITIM domain(TIGIT), lymphocyte activation gene-3(LAG-3), V-type immunoglobulin domain-containing suppressor of T cell activation(VISTA) and B7 family(B7-H3 and B7-H4), and co-stimulatory molecules, such as CD27, OX40, 4-1 BB, CD40, glucocorticoid-induced tumor necrosis factor receptor(GITR) and inducible co-stimulator(ICOS). In this review, the characteristics and preclinical/clinical progress of gynecological malignancies are briefly discussed.

关 键 词：免疫治疗 妇科肿瘤 T细胞受体 抗原递呈细胞 分子靶向治疗 

分 类 号：R737.3[医药卫生—肿瘤]